Impact of the 2014 American Academy of Pediatrics recommendation and of the resulting limited financial coverage by the Italian Medicines Agency for palivizumab prophylaxis on the RSV-associated hospitalizations in preterm infants during the 2016–2017 epidemic season: a systematic review of seven Italian reports

BACKGROUND: The only pharmacologic prophylaxis against respiratory syncytial virus (RSV) infection in preterm infants is the humanized monoclonal antibody palivizumab. After the 2014 modification of the American Academy of Pediatrics (AAP) recommendations, the Italian Medicines Agency (AIFA) limited...

Descripción completa

Detalles Bibliográficos
Autores principales: Cutrera, Renato, Wolfler, Andrea, Picone, Simonetta, Rossi, Giovanni A., Gualberti, Giuliana, Merolla, Rocco, Del Vecchio, Antonio, Villani, Alberto, Midulla, Fabio, Dotta, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6842491/
https://www.ncbi.nlm.nih.gov/pubmed/31706338
http://dx.doi.org/10.1186/s13052-019-0736-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6842491/
https://www.ncbi.nlm.nih.gov/pubmed/31706338
http://dx.doi.org/10.1186/s13052-019-0736-5

Ejemplares similares